YOUR SEARCH FOR Text 261 RESULTS
31 of Total
Corporate Governance | Incyte
Committee Charters Audit & Finance Committee (opens in new window) Compensation Committee (opens in new window) Nominating & Corporate
32 of Total
Events & Presentations | Incyte
Events Corporate Presentations Scientific Presentations The information contained in prior presentation materials and webcasts should be considered
33 of Total
Events & Presentations | Incyte
Events Corporate Presentations Scientific Presentations Date Title File Oct 26, 2026 ESMO 2026 - Incyte Investor Event ESMO 2026 - Incyte Investor
34 of Total
Incyte Investor Event - ESMO 2026 | Incyte
Events Corporate Presentations Scientific Presentations Incyte Investor Event - ESMO 2026 Oct 26, 2026 at 2:30 PM EDT Click here for Webcast
35 of Total
Q2 2026 Incyte Corporation Earnings Conference Call | Incyte
Events Corporate Presentations Scientific Presentations Q2 2026 Incyte Corporation Earnings Conference Call Jul 28, 2026 at 8:00 AM EDT Click here
36 of Total
Q3 2026 Incyte Corporation Earnings Conference Call | Incyte
Events Corporate Presentations Scientific Presentations Q3 2026 Incyte Corporation Earnings Conference Call Oct 29, 2026 at 8:00 AM EDT Add to
37 of Total
Financials | Incyte
Annual Reports Quarterly Reports SEC Filings The information contained in prior reports should be considered accurate only as of the date of the
38 of Total
Financials | Incyte
Annual Reports Quarterly Reports SEC Filings The information contained in prior press releases, reports, presentations and other materials should be
39 of Total
Financials | Incyte
Annual Reports Quarterly Reports SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly
40 of Total
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer | Incyte
View all news Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer October 24, 2026 at 7:00 AM EDT PDF Version
A New Frontier
in Hematology
Incyte proudly adds VGA039 and the
VIVID study to its hematology portfolio.